153 related articles for article (PubMed ID: 11956031)
21. [The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients].
ławicki S; Czygier M; Gacuta-Szumarska E; Knapp P; Szmitkowski M
Pol Merkur Lekarski; 2006 Nov; 21(125):465-8. PubMed ID: 17345841
[TBL] [Abstract][Full Text] [Related]
22. The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.
Al Sarakbi W; Mokbel R; Salhab M; Jiang WG; Reed MJ; Mokbel K
Anticancer Res; 2006; 26(6C):4985-90. PubMed ID: 17214375
[TBL] [Abstract][Full Text] [Related]
23. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
24. Significant correlation of matrix metalloproteinase and macrophage colony-stimulating factor serum concentrations in patients with head and neck cancer.
Kuropkat C; Duenne AA; Herz U; Renz H; Werner JA
Neoplasma; 2004; 51(5):375-8. PubMed ID: 15640942
[TBL] [Abstract][Full Text] [Related]
25. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
26. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
27. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin.
Aas T; Geisler S; Helle H; Børresen-Dale AL; Lønning PE; Akslen LA
Oncol Rep; 2005 Mar; 13(3):525-30. PubMed ID: 15706428
[TBL] [Abstract][Full Text] [Related]
29. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions.
Coskun U; Bukan N; Sancak B; Günel N; Ozenirler S; Unal A; Yucel A
Neoplasma; 2004; 51(3):209-13. PubMed ID: 15254675
[TBL] [Abstract][Full Text] [Related]
30. Vascular endothelial growth factor-C in patients with breast cancer.
Al-Mowallad A; Kirwan C; Byrne G; McDowell G; Li C; Stewart A; Al-Qouzi A; Kumar S
In Vivo; 2007; 21(3):549-51. PubMed ID: 17591368
[TBL] [Abstract][Full Text] [Related]
31. [Macrophage-colony stimulating factor and ovarian cancer].
Menditto A; Piscittelli V; Cassese F; Balbi GC; Balbi C; Cardone A
Minerva Ginecol; 1999; 51(7-8):261-4. PubMed ID: 10536419
[TBL] [Abstract][Full Text] [Related]
32. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
33. Parotid metastasis--an independent prognostic factor for head and neck cutaneous squamous cell carcinoma.
Ch'ng S; Maitra A; Lea R; Brasch H; Tan ST
J Plast Reconstr Aesthet Surg; 2006; 59(12):1288-93. PubMed ID: 17113505
[TBL] [Abstract][Full Text] [Related]
34. [Macrophage colony-stimulating factor for treatment of prostatic cancer with bone metastases].
Hayashi T; Kakehi R
Hinyokika Kiyo; 1993 Jan; 39(1):101-5. PubMed ID: 8460579
[TBL] [Abstract][Full Text] [Related]
35. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy.
Bozcuk H; Uslu G; Samur M; Yildiz M; Ozben T; Ozdoğan M; Artaç M; Altunbaş H; Akan I; Savaş B
Cytokine; 2004 Jul 21-Aug 7; 27(2-3):58-65. PubMed ID: 15242694
[TBL] [Abstract][Full Text] [Related]
36. [The plasma levels and diagnostic utility of stem cell factor (SCF) and macrophage-colony stimulating factor (M-CSF) in cervical cancer patients].
Lawicki S; Bedkowska E; Gacuta-Szumarska E; Knapp P; Szmitkowski M
Pol Merkur Lekarski; 2008 Jul; 25(145):38-42. PubMed ID: 18839612
[TBL] [Abstract][Full Text] [Related]
37. [Selected hematopoietic cytokines in patients with colorectal cancer].
Mroczko B; Ławicki S; Szmitkowski M; Czygier M; Okulczyk B; Piotrowski Z
Pol Merkur Lekarski; 2003 Nov; 15(89):416-9. PubMed ID: 14969133
[TBL] [Abstract][Full Text] [Related]
38. The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma.
Toy EP; Chambers JT; Kacinski BM; Flick MB; Chambers SK
Gynecol Oncol; 2001 Feb; 80(2):194-200. PubMed ID: 11161859
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
[TBL] [Abstract][Full Text] [Related]
40. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
